Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-092102
Filing Date
2021-07-14
Accepted
2021-07-14 16:08:21
Documents
2
Period of Report
2021-07-12

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2122186-2_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2122186-2_3seq1.xml 3 1602
2 EXHIBIT 24 tm2122186d2_ex24.htm EX-24 7970
  Complete submission text file 0001104659-21-092102.txt   10991
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Issuer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BLVD, SUITE 350 SOUTH SAN FRANCISCO CA 64080
Business Address
Judy Chou (Reporting) CIK: 0001871695 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38944 | Film No.: 211090318